Literature DB >> 9462720

Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression.

K Saito1, H Ishikura, T Kishimoto, Y Kawarada, T Yano, T Takahashi, H Kato, T Yoshiki.   

Abstract

Production of interleukin-6 (IL-6) by human pancreatic carcinoma cells inversely correlates with potentials for blood-borne metastasis to the liver in nude mice. IL-6 cDNA was transfected to PCI-43, one of our cultured pancreatic carcinoma cell lines that does not produce IL-6 and generates numerous metastases to the liver. An IL-6 high-producer clone (PCI-43h) generated few metastases; IL-6 production thus has a direct effect on metastasis, whereas other transfectants (PCI-43l and PCI-43n), which are IL-6 low-, and IL-6 non-producers, respectively, did generate metastases. Tumor-reactive IgG, which mediated antibody-dependent cellular cytotoxicity (ADCC) in vitro, was detected in sera from recipient nude mice inoculated with PCI-43h but not in sera from mice given PCI-43l, PCI-43n or parent PCI-43. Tumor-reactive IgM was detected in sera from all mice, irrespective of inoculated PCI-43 species, with a slight augmentation being noted in PCI-43h-inoculated nude mice. Severe combined immunodeficiency (SCID) beige mice were then used as recipients for PCI-43 species, and tumorigeneity was examined by s.c. inoculation of a suboptimal number of PCI-43 transfectants (1 x 10(6)/0.1 ml). Only PCI-43h formed palpable masses in SCID beige mice, whereas it first grew to be palpable but subsequently became not palpable in nude mice, thereby revealing a dual action of tumor-derived IL-6. Thus, tumor-derived IL-6 confers growth promotion in SCID beige mice, while the same cytokine exhibits anti-tumorigenic functions, presumably through humoral immune responses, in nude mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462720     DOI: 10.1002/(sici)1097-0215(19980119)75:2<284::aid-ijc18>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.

Authors:  S L Fu; J Pierre; T A Smith-Norowitz; M Hagler; W Bowne; M R Pincus; C M Mueller; M E Zenilman; M H Bluth
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

Review 2.  Mouse models of metastatic pancreatic adenocarcinoma.

Authors:  K Xie; B Wang; Q Shi; J L Abbruzzese; Q Xiong; X Le
Journal:  Int J Pancreatol       Date:  2001

3.  A new liver metastatic and peritoneal dissemination model established from the same human pancreatic cancer cell line: analysis using cDNA macroarray.

Authors:  Hiroki Nomura; Hidefumi Nishimori; Takahiro Yasoshima; Fumitake Hata; Hiroshi Tanaka; Futoshi Nakajima; Toshio Honma; Jun Araya; Kenjiro Kamiguchi; Hiroshi Isomura; Noriyuki Sato; Ryuichi Denno; Koichi Hirata
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

4.  Vaccination effect of interleukin-6-producing pancreatic cancer cells in nude mice: a model of tumor prevention and treatment in immune-compromised patients.

Authors:  T Yano; H Ishikura; H Kato; Y Ogawa; S Kondo; H Kato; T Yoshiki
Journal:  Jpn J Cancer Res       Date:  2001-01

5.  Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoprotein.

Authors:  Toru Otsuru; Shogo Kobayashi; Hiroshi Wada; Tsuyoshi Takahashi; Kunihito Gotoh; Yoshifumi Iwagami; Daisaku Yamada; Takehiro Noda; Tadafumi Asaoka; Satoshi Serada; Minoru Fujimoto; Hidetoshi Eguchi; Masaki Mori; Yuichiro Doki; Testuji Naka
Journal:  Cancer Sci       Date:  2019-02-04       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.